Completed PHASE2 INTERVENTIONAL 2-arm NCT00501202

Study for Safety and Effectiveness of RWJ-333369 (Carsibamate) for the Treatment of Diabetic Peripheral Neuropathy (DPN).

A Randomized, Double-Blind, Placebo-Controlled, Crossover Study of RWJ 333369 for the Treatment of Neuropathic Pain in Diabetic Peripheral Neuropathy.

Sponsor: SK Life Science, Inc.

Conditions Diabetic Mononeuropathy Diabetic Neuralgia Diabetic Neuropathy, Painful Diabetic Polyneuropathy

Interventions RWJ-333369 (carisbamate) placebo

Updated 8 times since 2017 Last updated: Apr 27, 2018 Started: Mar 31, 2007 Primary completion: May 31, 2008 Completion: May 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Diabetic Mononeuropathy and Diabetic Neuralgia, this trial is completed. The trial is conducted by SK Life Science, Inc. and has accumulated 8 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2
Nov 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Nov 2018 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

SK Life Science, Inc.

Data source: SK Life Science, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.